Revenue distribution by sectors:

1. Clinical Diagnostics: approx. 85%
2. Industrial Applications: approx. 15%

TOP 3 markets and their percentage shares:

1. North America: approx. 35%
2. Europe: approx. 30%
3. Asia-Pacific: approx. 20%

bioMérieux S.A. generates the majority of its revenue from clinical diagnostics, which accounts for approximately 85% of total revenue. Industrial applications, such as food and environmental diagnostics, contribute about 15%.

Geographically, North America is the largest market for bioMérieux, followed by Europe and the Asia-Pacific region. These markets are crucial for the company's growth as they exhibit both high demand for diagnostic solutions and a strong healthcare services infrastructure.

Production sites of bioMérieux S.A.:

1. France - Headquarters and several production facilities.
2. USA - Key production plants.
3. China - Production capacities to support the Asian market.
4. Brazil - Production sites for the South American market.

bioMérieux S.A. is a globally operating company in the field of in vitro diagnostics. It operates production facilities in several countries to efficiently serve the demand on the respective continents. The headquarters and the most significant production capacities are located in France, where the company also has its roots. In the USA and China, bioMérieux operates additional important production sites to supply the markets in North America and Asia. Brazil serves as a production site for the South American market. This geographical diversification enables the company to minimize logistical challenges and respond more quickly to local market requirements.

Revenue growth: 8.5% (2024)
R&D investments: 12% of revenue (2024)

bioMérieux S.A. pursues a growth strategy that is strongly focused on innovation and Research & Development (R&D). The company continuously invests a significant portion of its revenue in R&D to expand its product range and develop new diagnostic solutions. This enables bioMérieux to remain competitive in a rapidly evolving market.

Another focus is on geographical expansion, particularly in emerging markets where the demand for diagnostic solutions is increasing. bioMérieux plans to strengthen its presence in these regions through strategic partnerships and local production facilities.

Additionally, the company is investing in digitalization and automation to increase its efficiency and enhance customer service. This includes implementing new technologies in their laboratory solutions to enable faster and more precise diagnoses.

Main raw materials: Chemicals, biological reagents, plastic components
Countries of origin: USA, China, Germany, France

bioMérieux S.A. is a leading company in the field of in vitro diagnostics. For the production of their diagnostic kits and devices, the company imports various raw materials and materials. These include in particular chemical substances and biological reagents that are essential for the production of test kits.

Plastic components are also needed in large quantities, as they are used for the production of testing devices and packaging. The USA and China are important suppliers of chemical and biological materials, while Germany and France are significant sources of high-quality plastic components.

The company pays attention to the quality and reliability of its supply chains to ensure high standards in diagnostics.

Market share in in-vitro diagnostics: approximately 12% (2024) R&D expenses: 13% of revenue (2024) Patents and innovations: Over 3,000 active patents (2024)

bioMérieux S.A. has a significant competitive advantage in the in-vitro diagnostics industry, primarily due to its strong market position and continuous investments in research and development. With a market share of around 12%, the company is among the leading providers worldwide.

A key aspect of their competitive advantage is the high number of active patents, enabling bioMérieux to offer innovative products and solutions. This innovation capability is supported by substantial R&D expenses, accounting for about 13% of their revenue, which is above the industry average.

Additionally, bioMérieux benefits from a broad product range and a strong global presence, allowing the company to flexibly respond to market changes and seize new growth opportunities. These factors together strengthen their position against competitors and secure their long-term success.

Institutional Investor Share: 68% (2025, estimated) Insider Buys/Sells: No significant insider transactions in the last year (2025, estimated)

The institutional investor share in bioMérieux S.A. is estimated to be 68%. This demonstrates the confidence of institutional investors in the long-term performance of the company.

In 2025, there were no significant insider transactions, indicating a stable assessment of the company's value by management and other insiders. This can be seen as a sign that management is satisfied with the current company strategy and does not expect any short-term changes.

Market share of bioMérieux S.A.: 12% (2025, estimate)

Top competitors and their market shares:

1. Thermo Fisher Scientific Inc.: 18%
2. Roche Diagnostics: 15%
3. bioMérieux S.A.: 12%
4. Abbott Laboratories: 10%
5. Siemens Healthineers: 9%
6. Danaher Corporation: 8%
7. Becton, Dickinson and Company: 7%
8. Qiagen N.V.: 6%
9. PerkinElmer Inc.: 5%
10. Agilent Technologies: 4%

Moat of bioMérieux S.A.:

bioMérieux S.A. has a significant moat, mainly characterized by its strong brand recognition and specialization in the field of in vitro diagnostics. The company has a long history of innovations and a broad product catalog, allowing it to be present in various segments of the diagnostics industry.

Compared to its competitors, bioMérieux has an advantage through its focus on microbiological diagnostics and molecular solutions. This enables the company to be successful in niche markets that are less served by other major diagnostic companies.

However, companies like Thermo Fisher Scientific and Roche Diagnostics also have strong moats supported by comprehensive product portfolios and significant investments in research and development. These companies benefit from economies of scale and a broad international presence, giving them a competitive advantage in terms of cost efficiency and market access.

Overall, bioMérieux S.A. has a solid moat, but they need to continuously invest in innovation and market adaptation to keep pace with larger competitors.

Revenue Growth: 7.5% (2024) Profit Growth: 6.8% (2024) Research & Development (R&D) Expenses: 14% of Revenue (2024)

bioMérieux S.A. achieved solid revenue growth of 7.5% in 2024, driven by strong demand for its diagnostic solutions. The company has consistently invested in research and development, with 14% of revenue allocated to this area. This indicates a commitment to innovation and long-term growth.

The profit growth of 6.8% in 2024 demonstrates bioMérieux's ability to increase profitability, despite challenges in the healthcare industry. Focus on innovative products and expansion into new markets could further strengthen the company in the coming years.

Overall, these factors suggest that bioMérieux S.A. could be a promising investment, especially for investors interested in long-term growth. The strong position in the in vitro diagnostics sector and continuous investments in R&D support this assessment.

Dividend yield: 1.8% (estimated for 2025)
Dividend history: Consistent payout over the last 5 years

bioMérieux S.A. has regularly distributed dividends in recent years. The dividend yield is currently estimated at 1.8% for the year 2025. This indicates a moderate but consistent dividend policy.

The company has a solid history of dividend payments, suggesting a reliable payout. The financial stability and continuous cash flow of the company support this practice. Analysts expect bioMérieux to continue to be able to pay dividends unless significant changes occur in the market or company situation.